Guía de Práctica Clínica sobre Trastorno Bipolar - GuíaSalud

612. Eberhard-Gran M, Eskild A y Opjordsmoen S. Treating mood disorders during
pregnancy: Safety considerations. Drug Safety, 2005; 28 (8): 695-706.
613. Ortigado A, García A y JM. K. Anomalía de Ebstein y exposición al litio en el embarazo.
An pediatr 2006; 65: 626-642.
614. García L, Cardona X, Cuesta L, Delgado L, Grau M y Laceras M. Recomendaciones
terapéuticas en el embarazo, posparto y la lactancia. In: Soler-Insa P, Gascón J, editors.
Recomendaciones terapéuticas en los Trastornos Mentales. Barcelona: Ars Médica; 2005.
615. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM y Ryan LM.
The teratogenicity of anticonvulsant drugs. N Engl J Med, 2001; 344 (15): 1132-1138.
616. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern
RC, Morrison PJ y Craig J. Malformation risks of antiepileptic drugs in pregnancy: a
prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg
Psychiatry, 2006; 77 (2): 193-198.
617. O’Brien MDG-W, S.K. Management of epilepsy in women. Postgraduate Medical
Journal, 2005; 81: 278-285.
618. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR y Holmes LB. Increased
rate of major malformations in offspring exposed to valproate during pregnancy.
Neurology, 2005; 64 (6): 961-965.
619. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R y Nulman I. Major malformations
with valproic acid. Can Fam Physician, 2006; 52: 441-442, 444, 447.
620. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, Stewart PA,
Gaillard HL, Sachs ES y Wladimiroff JW. The risk of spina bifida aperta after firsttrimester
exposure to valproate in a prenatal cohort. Neurology, 1992; 42 (4 Suppl 5):
119-125.
621. Adab N, Kini U y Vinten J. The longer term outcome of children born to mothers with
epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2004; 75: 1575-1583.
622. Adab N, Tudur S, Vinten J, Williamson P y Winterbottom J. Common antiepileptic drugs
in pregnancy in women with epilepsy. : Cochrane Colaboration; 2004.
623. Vinten J, Adab N, Kini U, Gorry J, Gregg J y Baker GA. Neuropsychological effects of
exposure to anticonvulsant medication in utero. Neurology, 2005; 64 (6): 949-954.
624. Newport D, Fisher A, Graybeal S y Store Z. Psicofarmacología durante el embarazo y
lactancia. In: Schatzberg A, Nemeroff C, editors. Tratado de psicofarmacología.
Barcelona: Masson; 2006.
625. Lumley J, Watson L, Watson M y Bower C. Periconceptional supplementation with
folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst
Rev, 2001; (3): CD001056.
626. Duncan S, Mercho S, Lopes-Cendes I, Seni MH, Benjamin A, Dubeau F, Andermann F y
Andermann E. Repeated neural tube defects and valproate monotherapy suggest a
pharmacogenetic abnormality. Epilepsia, 2001; 42 (6): 750-753.
627. Artama M, Auvinen A, Raudaskoski T, Isojärvi I y Isojärvi J. Antiepileptic drug use of
women with epilepsy and congenital malformations in offspring. Neurology, 2005; 64:
1874-1878.
628. Montouris G. Importance of monotherapy in women across the reproductive cycle.
Neurology, 2007; 69 (24 Suppl 3): S10-16.
629. Wide K, Winbladh B, Tomson T, Sars-Zimmer K y Berggren E. Psychomotor
development and minor anomalies in children exposed to antiepileptic drugs in utero: a
prospective population-based study. Dev Med Child Neurol, 2000; 42 (2): 87-92.
630. Shor S, Koren G y Nulman I. Teratogenicity of lamotrigine. Can Fam Physician, 2007;
53 (6): 1007-1009.
631. Tomson T, Perucca E y Battino D. Navigating toward fetal and maternal health: the
challenge of treating epilepsy in pregnancy. Epilepsia, 2004; 45 (10): 1171-1175.
GUÍA DE PRÁCTICA CLÍNICA SOBRE TRASTORNO BIPOLAR 435